Investing

Disc Medicine : IRON

IRON

Stock Data

$66.91

$0.96 (1.46%)

Asset Type

Common Stock

Exchange

NASDAQ

Currency

USD

Country

USA

Sector

HEALTHCARE

Industry

BIOTECHNOLOGY

Disc Medicine, Inc., together with its subsidiaries, operates as a clinical-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and MWTX-003 for the treatment of polycythemia vera, and other hematologic disorders. The company's preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. The company was founded in 2017 and is headquartered in Watertown, Massachusetts.

All Disc Medicine Articles

2 Articles

Trey Thoelcke | Jun 23, 2024 at 8:45 AM EDT

Buffett Back at the Buy Window, Plus Insider Buying at a Refiner, Biotechs, and More

Warren Buffett has purchased more of his favorite energy stock. A couple of biotech stocks and a recreational boat maker…

Lee Jackson | Jun 12, 2023 at 8:50 AM EDT

Monday’s Top Analyst Upgrades and Downgrades: Activision Blizzard, Adobe, Caesars, Corning, PayPal, Target, Twilio and More

Monday's top analyst upgrades and downgrades included Activision Blizzard, Adobe, Caesars Entertainment, Corning, DocuSign, Park Hotels & Resorts, PayPal, Target,…